Case No.: 21592YP Page No.: 4

#### **Listing of Claims**

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I):

wherein

Y<sup>1</sup> is CH or N;

Q1 is selected from the group consisting of

- (1) -OH, and
- $(2) NH_2;$

Q<sup>2</sup> and Q<sup>3</sup> independently selected from the group consisting of

- (1) hydrogen, and
- (2) halogen;

Ra is selected from the group consisting of

- (1) hydrogen,
- (2) -C<sub>1-10</sub> alkyl, wherein said alkyl is unsubstituted or substituted with one or more fluoro, and
- (3) -C<sub>3-8</sub> cycloalkyl;

Rb is selected from the group consisting of

- (1) hydrogen,
- $(2) C_{1-10}$  alkyl,
- (3) -C<sub>1-3</sub> alkyl-aryl, wherein said aryl is selected from the group consisting of phenyl and naphthyl,
- (4) -C3-8 cycloalkyl,

Case No.: 21592YP Page No.: 5

wherein said cycloalkyl, alkyl and aryl are unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d)  $-O-C_{1-10}$  alkyl,
- (5) –(CH<sub>2</sub>)<sub>n</sub>-NR<sup>c</sup>R<sup>d</sup> wherein R<sup>c</sup> and R<sup>d</sup> are selected from the group consisting of hydrogen and C<sub>1-10</sub> alkyl, and n is 2, 3 or 4, and
- (6) -(CH2)n'-O-Re, wherein Re is selected from the group consisting of
  - (a) C<sub>1-10</sub> alkyl,
  - (b) -C<sub>0-3</sub> alkyl-aryl, wherein said aryl is selected from the group consisting of phenyl and naphthyl,

wherein said alkyl and aryl are unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C<sub>1-10</sub> alkyl,

and n' is 1, 2, 3 or 4;

m is 1 or 2;

- R<sup>1</sup> is (1) aryl selected from the group consisting of phenyl and napthyl, or
  - (2) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
  - (3) -C<sub>1-10</sub> alkyl, and
  - (4) -C3-8 cycloalkyl,

wherein said aryl, heteroaryl, alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -O-C<sub>1-10</sub> alkyl,

Case No.: 21592YP Page No.: 6

- (e)  $-C_{1-10}$  alkyl,
- (f) -C3-8 cycloalkyl,
- (g) aryl selected from the group consisting of phenyl and napthyl, or
- (h) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;

R<sup>2</sup> is selected from the group consisting of:

- (1)  $(R^4-SO_2)N(R^7)$ -, wherein  $R^4$  is
  - (a) -C<sub>1-10</sub> alkyl,
  - (b) -C3-8 cycloalkyl,

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C<sub>1-10</sub> alkyl,
- (v) -C<sub>1-10</sub> alkyl,
- (vi) -C3-8 cycloalkyl,
- (vii) aryl selected from the group consisting of phenyl and napthyl, or (viii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;

and said aryl and heteroaryl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C<sub>1-10</sub> alkyl,
- (E) -C3-8 cycloalkyl, or
- (F) -C<sub>1-10</sub> alkyl,

Case No.: 21592YP

Page No.: 7

(c) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

> wherein said heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C<sub>1-10</sub> alkyl,
- (v) -C3-8 cycloalkyl, or
- (vi) -C<sub>1-10</sub> alkyl,

(d) -(CH<sub>2</sub>)<sub>x</sub>-NRfRg wherein Rf and Rg are selected from the group consisting of hydrogen and  $C_{1-10}$  alkyl, and x is 0, 1, 2, 3 or 4, or  $R^f$  and Rg, together with the nitrogen atom to which they are attached form the group



wherein y is 1 or 2, Y<sup>5</sup> is -CHR<sup>21</sup>, -O- or NR<sup>21</sup>, wherein R<sup>21</sup> is selected from the group consisting of;

- (i) hydrogen, and
- (ii) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C<sub>1-10</sub> alkyl, or
- (E) -C<sub>3-8</sub> cycloalkyl;

Case No.: 21592YP Page No.: 8

R<sup>7</sup> is selected from the group consisting of

- (a) hydrogen, and
- (b) -C<sub>1-10</sub> alkyl,
- (c) aryl selected from the group consisting of phenyl and napthyl, or
- (d) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl

wherein said alkyl, aryl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C<sub>1-10</sub> alkyl,
- (v) -C3-8 cycloalkyl,
- (vi) aryl selected from the group consisting of phenyl and napthyl, or (vii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said cycloalkyl, aryl or heteroaryl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D)  $-O-C_{1-10}$  alkyl,
- (E) -C<sub>3-8</sub> cycloalkyl, or
- (F) aryl selected from the group consisting of phenyl and napthyl;
- (e)  $-(CH_2)_y$ '- $NR^hR^i$  wherein  $R^h$  and  $R^i$  are selected from the group consisting of hydrogen and  $C_{1-10}$  alkyl, and y' is 1, 2, 3 or 4, or or  $R^h$  and  $R^i$ , together with the nitrogen atom to which they are attached from the group

Case No.: 21592YP Page No.: 9



wherein y' is 1 or 2, Y6 is -CHR<sup>22</sup>, -O- or NR<sup>22</sup>, wherein R<sup>22</sup> is selected from the group consisting of;

- (i) hydrogen, and
- (ii) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C<sub>1-10</sub> alkyl, or
- (E) -C3-8 cycloalkyl,

or R<sup>4</sup> and R<sup>7</sup> are linked together to form the group

(a)

wherein z is 1, 2 or 3; or

(b)

wherein z is 1, 2 or 3

(2)

Case No.: 21592YP Page No.: 10

# wherein R<sup>8</sup> is selected from the group consisting of

- (a) -CN,
- (b) hydrogen, and
- (c) tetrazolyl;

(3)

(4)

$$\bigvee_{\gamma_{2}} \bigvee^{Y^{2}}$$

wherein Y<sup>2</sup> is -NH=CH- or -CH=NH-;

## R<sup>3</sup> is selected from the group consisting of

wherein Y<sup>3</sup> is CR<sup>6c</sup> or N;

 $R^5$  is  $C_{1-10}$  alkyl or  $C_{1-2}$  perfluoroalkyl;

R6a, R6b, and R6c are independently selected from the group consisting of:

(1) hydrogen,

Case No.: 21592YP Page No.: 11

(2) halo,

- $(3) C_{1-10}$  alkyl,
- (4) –OH,
- (5) –CN,
- (6) -C3-8 cycloalkyl, and
- $(7) O C_{1-10}$  alkyl;

R9 and R10 are independently selected from the group consisting of

- (1) hydrogen,
- (2) -C<sub>1-10</sub> alkyl, and
- (3) -C3-8 cycloalkyl,

wherein said alkyl and cycloalkyl are unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -O-C<sub>1-10</sub> alkyl,
- (e) -C3-8 cycloalkyl, and
- (f) -NRj Rk wherein Rj and Rk are C1-10 alkyl;

or R9 and R10 are joined together with the nitrogen atom to which they are attached to form

wherein w is 1, 2 or 3, and

R<sup>23</sup> is selected from the group consisting of

- (a) hydrogen,
- (b) -C<sub>1-10</sub> alkyl,
- (c) -C<sub>3-8</sub> cycloalkyl,
- (d) -C2-10 alkenyl,
- (e) -C2-10 alkynyl,
- (f) -(CH2)p-phenyl,

Case No.: 21592YP Page No.: 12

(g) -(CH<sub>2</sub>)<sub>p</sub>-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein p is 0 or 1, and

wherein said alkyl, alkenyl, alkynyl, cycloalkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii)  $-C_{1-10}$  alkyl,
- (iii) -OH,
- (iv) -CN,
- (v) -C3-8 cycloalkyl, or
- (vi) -O-C<sub>1-10</sub> alkyl;

R<sup>11</sup> is selected from the group consisting of

- (1) CH -
- (2) –CH<sub>2</sub>–,
- (3) O -, and
- $(4) NR^{17} -$

provided that when  $R^{11}$  is -CH- the dotted line forms a bond and when  $R^{11}$  is -CH<sub>2</sub>-, -O- or -NR<sup>17</sup>- the dotted line is absent;

 $R^{17}$  is hydrogen or  $C_{1-10}$  alkyl, wherein said  $C_{1-10}$  alkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -C3-8 cycloalkyl,
- (e) -O-C<sub>1-10</sub> alkyl,
- (f) -(CH<sub>2</sub>)<sub>q</sub>-phenyl, wherein q is 1 or 2, and
- (g) -NR18R19, and

Case No.: 21592YP Page No.: 13

wherein  $R^{18}$  and  $R^{19}$  are independently selected from the group consisting of

- (i) hydrogen, or
- (ii) C<sub>1-10</sub> alkyl;

or R<sup>18</sup> and R<sup>19</sup>, together with the nitrogen atom to which they are attached, form the group



wherein q' is 1 or 2,  $Y^7$  is -CHR<sup>24</sup>, -O- or NR<sup>24</sup>, wherein R<sup>24</sup> is selected from the group consisting of;

- (a) hydrogen, and
- (b) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C<sub>1-10</sub> alkyl, or
- (v) -C3-8 cycloalkyl;

R<sup>26</sup> is selected from the group consisting of

- (1) hydrogen,
- (2)  $-C_{1-3}$  alkyl;

R12 is selected from the group consisting of

- (1) hydrogen,
- (2) -C<sub>1-10</sub> alkyl, wherein said alkyl is unsubstituted or substituted with one or more
  - (a) halo,
  - (b) -OH,
  - (c) -CN,
  - (d) -C3-8 cycloalkyl,
  - (e) -O-C<sub>1-10</sub> alkyl, or
  - $(f) NH_2,$

Case No.: 21592YP Page No.: 14

- (3) halo,
- (4) -C<sub>3-8</sub> cycloalkyl,
- (5) aryl selected from the group consisting of phenyl and napthyl, and
- (6) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said aryl and heteroaryl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d)  $-O-C_{1-10}$  alkyl,
- (e) -C3-8 cycloalkyl, or
- (f) -C<sub>1-10</sub> alkyl;

R<sup>13</sup> is selected from the group consisting of

- (1) hydrogen,
- (2) C<sub>1-10</sub> alkyl, and
- (3) -C3-8 cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -C3-8 cycloalkyl,
- (e) -O-C<sub>1-10</sub> alkyl, and
- (f)  $-C_{1-10}$  alkyl;

R<sup>14</sup> is selected from the group consisting of

- (1) -C<sub>1-10</sub> alkyl, and
- (2) -C3-8 cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,

Case No.: 21592YP Page No.: 15

- (d) -C3-8 cycloalkyl,
- (e) -O-C<sub>1-10</sub> alkyl, or
- (f)  $-C_{1-10}$  alkyl;
- (3) -(CH<sub>2</sub>)<sub>V</sub>-NR<sup>15</sup>R<sup>16</sup>, wherein v is 2, 3 or 4, and wherein R<sup>15</sup> and R<sup>16</sup> are independently selected from the group consisting of
  - a) hydrogen, or
  - b)  $C_{1-10}$  alkyl, wherein said  $C_{1-10}$  alkyl is unsubstituted or substituted with one or more
    - (i) halo,
    - (ii) -OH,
    - (iii) -CN,
    - (iv) -C3-8 cycloalkyl, or
    - (v)  $-O-C_{1-10}$  alkyl;

or  $R^{15}$  and  $R^{16}$ , together with the nitrogen atom to which they are attached, form the group



wherein s is 1 or 2, Y<sup>4</sup> is -CHR<sup>24</sup>-, -O- or -NR<sup>24</sup>-, wherein R<sup>24</sup> is selected from the group consisting of

- (i) hydrogen, and
- (ii) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C<sub>1-10</sub> alkyl, or
- (E) -C3-8 cycloalkyl,
- 4) -(CH<sub>2</sub>)<sub>r</sub>-phenyl, wherein r is 1, 2, 3, or 4, and

wherein said phenyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,

Case No.: 21592YP Page No.: 16

(c) -CN,

- (d) -O-C<sub>1-10</sub> alkyl,
- (e) -C<sub>3-8</sub> cycloalkyl, or
- (f) -C<sub>1-10</sub> alkyl;

or R<sup>13</sup> and R<sup>14</sup>, together with the nitrogen atom to which they are attached, form the group

wherein u is 1 or 2,  $Y^8$  is -CHR<sup>25</sup>-, -O- or -NR<sup>25</sup>-, wherein R<sup>25</sup> is selected from the group consisting of

- (a) hydrogen,
- (b) C<sub>1-10</sub> alkyl,
- (c) -(CH2)t-phenyl,
- (d) -(CH<sub>2</sub>)<sub>t</sub>-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein t is 0 or 1, and

wherein said alkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -C1-10 alkyl,
- (iii) -OH,
- (iv) -CN,
- (v) -C3-8 cycloalkyl, or
- (vi) -O-C<sub>1-10</sub> alkyl;

and pharmaceutically acceptable salts thereof.

2. (Original) The compound of Claim 1 wherein Ra and Rb are both hydrogen.

Case No.: 21592YP Page No.: 17

3. (Original) The compound of Claim 1 wherein R<sup>a</sup> is hydrogen and R<sup>b</sup> is C<sub>1-10</sub> alkyl.

- 4. (Original) The compound of Claim 1 wherein m is 1 and R<sup>1</sup> is selected from the group consisting of
  - (1) phenyl, unsubstituted or substituted in one or two positions with halo; and
  - (2) thienyl.
  - 5. (Original) The compound of Claim 1 wherein  $R^2$  is  $(R^4-SO_2)N(R^7)$ -.
  - 6. (Original) The compound of Claim 5 wherein R4 and R7 are each C<sub>1-6alkyl</sub>.
  - 7. (Original) The compound of Claim 1 wherein  $\mathbb{R}^3$  is (1)

$$\begin{array}{c|c}
R^{6a} \\
R^{6b} & \Pi \\
\ddot{Y}^{3} & H \\
R^{5} & O
\end{array}$$

wherein  $Y^3$  is CHR6c,  $R^5$  is methyl,  $R^{6a}$  and  $R^{6c}$  are hydrogen and  $R^{6b}$  is fluoro.

8. (Original) The compound of Claim 1 wherein  $\mathbb{R}^3$  is (1)

$$R^{6a}$$

$$R^{6b}$$

$$Y^{3}$$

$$R^{5}$$

$$O$$

Y<sup>3</sup> is N, R<sup>5</sup> is C<sub>1-2</sub> perfluoroalkyl, and R<sup>6a</sup> and R<sup>6b</sup> are hydrogen.

9. (Original) The compound of Claim 1 wherein R<sup>3</sup> is (2)

Case No.: 21592YP Page No.: 18

and  $R^9$  and  $R^{10}$  are each unsubstituted  $C_{1-10}$  alkyl, or  $R^9$  and  $R^{10}$  are joined together with the nitrogen atom to which they are attached to form attached to form

wherein w is 1;

 $R^{23}$  is  $-(CH_2)_p$ -phenyl or  $-(CH_2)_p$ -heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl, wherein the phenyl and heteroaryl are unsubstituted or substituted with one or more

wherein the phenyl and heteroaryl are unsubstituted or substituted with one or more chloro, and p is 0.

10. (Original) The compound of Claim 1 wherein R<sup>3</sup> is (3)

R<sup>11</sup> is NR<sup>17</sup> wherein R<sup>17</sup> is hydrogen or C<sub>1-3</sub> alkyl, and R<sup>12</sup> is hydrogen or methyl.

11. (Original) The compound of Claim 1 wherein R<sup>3</sup> is (4)

 $R^{13}$  is hydrogen and  $R^{14}$  is –(CH<sub>2</sub>)<sub>v</sub>-NR<sup>15</sup>R<sup>16</sup> wherein v is 2 and R<sup>15</sup> and R<sup>16</sup> are each C<sub>1-10</sub> alkyl, which is unsubstituted or substituted with –OH, -CN or –OCH<sub>3</sub>.

12. (Original) The compound of Claim 1 wherein R<sup>3</sup> is (4)

Case No.: 21592YP Page No.: 19

wherein R<sup>13</sup> and R<sup>14</sup>, together with the nitrogen atom to which they are attached, form the group

wherein u is 1 or 2, Y8 is -CHR<sup>25</sup>-, -O- or -NR<sup>25</sup>-.

#### 13. (Original) The compound of Claim 1 which is a compound of formula (II)

wherein Q<sup>1</sup>, Q<sup>2</sup>, Q<sup>3</sup>, R<sup>a</sup>, R<sup>b</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>12</sup>, R<sup>17</sup>, R<sup>26</sup> and m are as defined in Claim 1, and pharmaceutically acceptable salts thereof.

#### 14. (Original) The compound of Claim 1 which is a compound of formula (III)

$$R^{14} \longrightarrow N \longrightarrow Q^{2} \longrightarrow R^{a} \longrightarrow Q^{1}$$

$$R^{13} \longrightarrow Q^{3} \longrightarrow R^{1}$$

$$R^{1} \longrightarrow R^{1}$$

$$R^{1} \longrightarrow R^{1}$$

$$R^{1} \longrightarrow R^{1}$$

wherein  $Q^1$ ,  $Q^2$ ,  $Q^3$ ,  $R^a$ ,  $R^b$ ,  $R^1$ ,  $R^2$ ,  $R^{13}$ ,  $R^{14}$  and m are defined as in Claim 1, and pharmaceutically acceptable salts thereof.

#### 15. (Original) The compound of Claim 1 which is a compound of formula (IV):

Case No.: 21592YP Page No.: 20

$$\begin{array}{c|c}
R^2 & Q^2 & R^a \\
\hline
Q^3 & Q & Q^1 \\
\hline
IV & R^1
\end{array}$$

wherein  $Q^1$ ,  $Q^2$ ,  $Q^3$ ,  $R^a$ ,  $R^b$ ,  $R^1$ ,  $R^2$  and m are as defined in Claim 1, and  $R^3$  is (1) or (2) as defined in Claim 1, and pharmaceutically acceptable salts thereof.

16. (Amended) A compound of claim 1 which is selected from the group consisting of

N-SO <sub>2</sub> Me  N-SO <sub>2</sub> Me  N-SO <sub>2</sub> Me  N-SO <sub>2</sub> Me	
D T T T T T T T T T T T T T T T T T T T	H Z H
	O H N H N H F

O S O H N O H F F	
D C C C C C C C C C C C C C C C C C C C	H Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z

	O S H N OH F
F O H O H O H O H O H O H O H O H O H O	H N OH
	HO H
	HO Y

O, O N, S N NH <sub>2</sub>	D H NH2
H NH2	O B H Z H O H F F
H Z H	O P P P P P P P P P P P P P P P P P P P

H OH S	H NH2
H NH2	NC H NH <sub>2</sub> N Ph
NC H NH2 N Ph	NC H OH N Ph
NC H OH N Ph	NC H NH <sub>2</sub> N = Ph
NC H NH <sub>2</sub> N = Ph	NC H NH <sub>2</sub> N H NH <sub>2</sub> Ph

MeO <sub>2</sub> S.  H H N H OH N Ph	F H NH2 N S
MeO <sub>2</sub> S.  H N H NH <sub>2</sub> CF <sub>3</sub> O O Ph	O S N H OH Ph
N HX OH	
O N O O O O O O O O O O O O O O O O O O	N NH OH
CZ O DH OH	ON OH F

N NH OH	
F CN H OH	CN HN OH F F S
CN CN O N O O S	Z HZ OH
NC H OH	O S O O O O O O O O O O O O O O O O O O
	N OH

NH2 N NH2	NH <sub>2</sub>
NH <sub>2</sub>	NH <sub>2</sub>
NH <sub>2</sub>	ON N NH2 F
NH2 F	N N N N N N N N N N N N N N N N N N N

NH <sub>2</sub> F	F N O N I I I I I I I I I I I I I I I I I
NH <sub>2</sub> F	NH <sub>2</sub> F
NH <sub>2</sub> F	O S O O O O O O O O O O O O O O O O O O

NH <sub>2</sub>	
NH <sub>2</sub>	NH <sub>2</sub>
NH <sub>2</sub>	NH <sub>2</sub>
NH <sub>2</sub>	

NH <sub>2</sub> F	NH <sub>2</sub> F
F NH <sub>2</sub>	NH <sub>2</sub> F
NH <sub>2</sub> F	NH <sub>2</sub> F
NH <sub>2</sub> F	O O O O O O O O O O O O O O O O O O O

NH <sub>2</sub>	NH <sub>2</sub> F
NH <sub>2</sub> F	NH2 F
NH <sub>2</sub>	NH <sub>2</sub>
NH <sub>2</sub>	NH <sub>2</sub> CN
	O NH <sub>2</sub> F

	NH <sub>2</sub>
NH <sub>2</sub>	NH <sub>2</sub>
NH2 NH2 NH2	NH <sub>2</sub>
NH2 NH2 F	NH <sub>2</sub>

NH <sub>2</sub>	NH <sub>2</sub>
H NH2 F F	NH <sub>2</sub>
HN NH2 NH2	NH <sub>2</sub> NH <sub>2</sub> FF
NH <sub>2</sub> I	NH2* FF
O N NH2	NH <sub>2</sub>

NH <sub>2</sub> F F	
N CI H NH2 F	O D D D D D D D D D D D D D D D D D D D
ON O	O SH <sub>2</sub>

and pharmaceutically acceptable salts thereof.

17. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

## 18. (Canceled)

19. (Original) A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Claim 1.

## 20. (Canceled)